Clinical CDMO
Products
Information
- Under one single roof together with discovery and pre-clinical CRO departments, capitalizing on the previously in-house gained molecule know-how, intact project teams and existing legal agreements
- Stable, proprietary IcoCell® CHO cell line development platform with competitive titers & timelines, fee-for-service, license, royalty and milestone-free, with up to 10g/L titers even at non-optimized stable clone pool stage
- Experience with mAbs, bi-/multi-specifics, mAb-like proteins, Fc fusions, rec. proteins, etc.
- Intermittent stable IcoCell® CHO clone pools with g/L titers
- Can start late & parallel in discovery already, saving 4 months’ time in CMC section
- Clone selection of stable, high-titer clonal cell lines, which are process-proven and GMP-ready
- USP, DSP & analytical development, non-GMP manufacturing
- Pre-formulation development, stability studies, etc.
- GMP manufacturing on site with latest 50L, 200L & 1000L single-use bioreactor equipment
- Strategic partnership with European linker-toxin-conjugating company for ADC’s GMP manufacturing
